Neal J Meropol, MD

Recent Publications
As Of May 25, 2007

In Press

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, and Cohen RB. Mapatumumab, a fully human monoclonal antibody with agonist activity to TRAIL-R1: a phase I, pharmacokinetic and biologic correlative study. J Clin Oncol, in press.

Buzaglo JS, Millard JL, Ridgway CG, Ross EA, Antaramian SP, Miller SM, Meropol NJ. An internet method to asses cancer patient information needs and enhance doctor-patient communication: a pilot study. J Cancer Educ, in press.

Coups EJ, Manne SL, Meropol NJ, Weinberg DS. Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiology, Biomarkers & Prevention, in press.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, and Benson III, AB. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol, in press.

Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother, in press.

Buzaglo JS, Millard JL, Ridgway CG, Ross EA, Antaramian SP, Miller SM, Meropol NJ. An internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study. J Cancer Educ, in press.

Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P. Barriers to clinical trial participation as perceived by oncologists and patients. J NCCN, in press.

Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG PET with outcome after chemo-radiation in patients with esophageal carcinoma. Int J Rad Oncol Biol Physics, in press.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris III HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, and Mauro DJ. Expression of epiregulin and amphiregulin and K-RAS mutation status are associated with disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol, in press.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Cancer, in press.

2007

Coups EJ, Manne SL, Meropol NJ, Weinberg DS. Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiology, Biomarkers ’Dwyer PJ, Meropol NJ, Catalano PJ, Benson III A.B. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Annals Oncol 17:1399-1403, 2006.

Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients' decision-making process regarding participation in phase 1 oncology research. J Clin Oncol 24:4479-4484, 2006.

Meropol NJ. A turning point for colorectal cancer clinical trials. J Clin Oncol 24:3322-3324, 2006.

Sundermeyer ML, Lessin SR, Meropol NJ. Targeted therapies in colorectal cancer: complications and management. Current Colorectal Cancer Reports 2:125-133, 2006.

Meropol NJ, Buzaglo JS, Miller SM, Sheth HR, Stearman BJ, Stanton L. Genetic and family-related issues within a complex disease model: colorectal cancer. In S.M. Miller, S. McDaniel, J. Rolland, ™) in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22:1201-1208, 2004.

Sasson, A.R., Wetherington, R.W., Hoffman, J.P., Ross, E.A., Cooper, H., Meropol, N.J., Freedman, G., Pingpank, J.F., Eisenberg, B.L. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas. Int. J. Gastrointest. Cancer 34:121-127, 2004.

Shields, A.F., Zalupski, M.M., Marshall, J.L., Meropol, N.J. Treatment of advanced colorectal cancer with oxaliplatin and capecitabine: A phase II trial. Cancer 100:531-537, 2004.

Subhi, A.L., Tang, B., Balsara, B.R., Altomare, D.A., Testa, J.R., Cooper, H.S., Hoffman, J.P., Meropol, N.J., Kruger, W.D. Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin. Cancer Res. 10:7290-7296, 2004.

Meropol NJ, Castel L, Schulman KA, Weinfurt KP. Physician-patient communication in phase I cancer trials. Response to correspondence. J Clin Oncol 22: 572-573, 2004.

Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? Oncology, 18:479-488, 2004.

2003

Cohen, S.J., Ho, L., Ranganathan, S., Abbruzzese, J.L., Alpaugh, K., Beard, M., Lewis, N.L., McLaughlin, S., Rogatko, A., Ruixo, J.J.P., Thistle, A.M., Verhaeghe, T., Wang, H., Weiner, L.M., Wright, J.J., Hudes, G.R., Meropol, N.J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21:1301-1306, 2003.

Cohen, S.J., Meropol, N.J. Commentary: understanding and managing chemotherapy-induced diarrhea. J Supportive Oncol. 1:38-41, 2003.

Cortellino, S., Turner, D., Masciullo, V., Schepis, F., Albino, D., Daniel, R., Skalka, A.M., Meropol, N.J., Alberti, C., Larue, L.,

Bellacosa, A. The base excision repair enzyme MED1 mediates DNA damage response to anti-tumor drugs and is associated with mismatch repair system integrity. Proc. Natl. Acad. Sci. USA 100:15071-15076, 2003.

Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:60-65, 2003.

Lewis, N.L., Meropol, N.J. Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer 3:154-64, 2003.

Mandelblatt, J.S., Edge, S.B., Meropol, N.J., Senie, R., Tsangaris, T., Grey, L., Peterson, B.M. Jr., Hwang, Y.T., Kerner, J., Weeks, J. Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J. Clin. Oncol. 21:855-63, 2003.

Manne, S., Markowitz, A., Winawer, S., Guillem, J., Meropol, N.J., Haller, D., Rakowski, W., Babb, J., Jandorf, L., Duncan, T. Understanding intention to undergo colonoscopy among intermediate risk siblings of colorectal cancer patients: a test of a mediational model. Prev. Med. 36:71-84, 2003.

Meropol, N.J., Weinfurt, K.P., Burnett, C.B., Balshem, A., Benson, A.B., III, Castel, L., Corbett, S., Diefenbach, M., Gaskin, D., Li, Y., Manne, S., Marshall, J., Slater, E., Sulmasy, D.P., Rowland, J.H., Van Echo, D., Washington, S., Schulman, K.A. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physicianpatient communication. J. Clin. Oncol. 21:2589-2596, 2003.

Meropol, N.J., Somer, R.A., Gutheil, J., Pelley, R.J., Modiano, M.R., Rowinsky, E.K., Rothenberg, M.L., Redding, S.W., Serdar, C.M., Yao, B., Heard, R., Rosen, L.S. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J. Clin. Oncol. 21:1452-1458, 2003.

Meropol, N.J., Weinfurt, K.P., Schulman, K.A. Phase I trials: physician and patient perceptions. Response to correspondence. J. Clin. Oncol. 21:4659-4660, 2003.

Schuchter, L., Meropol, N.J., Winer, E.P., Hensley, M.L., Somerfield, M.R. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol. 4:593, 2003.

Weinfurt, K.P., Castel, L.D., Li, Y., Sulmasy, D.P., Balshem, A., Benson, III A.B., Burnett, C.B., Gaskin, D.J., Marshall, J.L., Slater, E., Schulman, K.A., Meropol, N.J. The relationship between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166-175, 2003.

Weinfurt, K.P., Sulmasy, D.P., Schulman, K.A., Meropol, N.J. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theoretical Med. Bioethics 24:329-344, 2003.

Lewis NL, Meropol NJ. Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer, 3:154-164, 2003.

Cohen SJ, Meropol NJ. Commentary: understanding and managing chemotherapy-induced diarrhea. J Supportive Oncol 1:38-41, 2003.

Schuchter L, Meropol NJ, Winer EP, Hensley ML, Somerfield MR. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol, 4:593, October 2003.

Meropol NJ, Weinfurt KP, Schulman KA. Phase I trials: physician and patient perceptions. Response to correspondence. J Clin Oncol 21: 4659-4660, 2003.

2002

Arnoletti, J.P., Hoffman, J.P., Ross, E.A., Kagan, S.A., Meropol, N.J., Freedman, G., Eisenberg, B. Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas. Am. Surg. 68:330-335, 2002.

Cohen, S.J., Leichman, C.G., Yeslow, G., Beard, M., Proefrock, A., Roedig, B., Damle, B., Letrent, S.P., DeCillis, A.P., Meropol, N.J. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin. Cancer Res. 8:2116-2122, 2002.

Cohen, S.J., Meropol, N.J. Drug development in pancreatic cancer: finally, biology begets therapy. Int. J. Gastrointest. Cancer 32(2-3):91-106, 2002.

Edge, S.B., Gold, K., Berg, C., Meropol, N.J., Tasangaris, T., Gray, L., Peterson, B., Hwang, Y-T., Mandelblatt, J.S. Patient and provider characteristics affecting use of axillary dissection in older women with stage I/II breast cancer. Cancer 94:2534-2544, 2002.

Fleming G.F., Meropol, N.J., Rosner, G.L., Hollis, D.R., Carson, W.E. 3rd, Caligiuri, M., Mortimer, J., Tkaczuk, K., Parihar, R., Schilsky, R.L., Ratain, M.J. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of Cancer and Leukemia Group B 9661. Clin. Cancer Res. 8: 3718-27, 2002.

Lewis, N.L., Scher, R., Gallo, J.M., Engstrom, P.F., Szarka, C.E., Litwin, S., Adams, A.L., Kilpatrick, D., Brady, D., Weiner, L.M., Meropol, N.J. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemother. Pharmacol. 50:257-265, 2002.

Liang, W., Burnett, C.B., Rowland, J.H., Meropol, N.J., Eggert, L., Hwang, Y., Silliman, R.A., Weeks, J.C., Mandelblatt, J.S. Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J. Clin. Oncol. 20:1008-1016, 2002.

Mandelblatt, J.S., Edge, S.B., Meropol, N.J., Senie, R., Tsangaris, T., Grey, L., Peterson, B., Hwang, Y.T., Weeks, J.C. Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer 95:2445-54, 2002.

Manne, S., Markowitz, A., Winawer, S., Meropol, N.J., Haller, D., Rakowski, W., Babb, J., Jandorf, L. Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol. 21:3-15, 2002.

Meropol, N.J., Lewis, N.L., Frucht, H. Colorectal cancer: a practical overview. Mosby Medical Communications, Philadelphia, 2002.

Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O'Neil, J.D., Groene, W.S., Roberts, M.S., Rabin, H., Bamat, M.K., Lorence, R.M. A Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20(9):2251-2266, 2002.

Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus 5-fluorouracil/leucovorin. Response to correspondence. J. Clin. Oncol. 20:1145-1146, 2002.

Schuchter, L.M., Hensley, M.L., Meropol, N.J., Winer, E.P., for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Protectants Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 20:2895-2903, 2002.

Cohen SJ, Meropol NJ. Drug development in pancreatic cancer: finally, biology begets therapy. Int J Gastrointest Cancer 32:91-106, 2002.

Meropol NJ, Lewis NL, Frucht H. Colorectal cancer: a practical overview. Mosby Medical Communications, Philadelphia, 2002.

Schuchter LM, Hensley ML, Meropol NJ, Winer EP, for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Protectants Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20: 2895-2903, 2002.

Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus 5-fluorouracil/leucovorin. Response to correspondence. J Clin Oncol 20: 1145-1146, 2002.

2001

Balsara, B.R., Pei, J., De Rienzo, A., Simon, D., Tosolini, A., Lu, Y.Y., Shen, F.M., Fan, X., Lin, W.Y., Buetow, K.H., London, W.T., Testa, J.R. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 30:245-253, 2001.

Bellacosa, A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 8:1076-1092, 2001.

Burnett, C.B., Koczwara, B., Pixley, L., Blumenson, L.E., Hwang, Y.T., Meropol, N.J. Nurses' attitudes toward clinical trials at a comprehensive cancer center. Oncol. Nurs. Forum 28(7):1187-1192, 2001.

Clapper, M.L., Chang, W-C., Meropol, N.J. Chemoprevention of colorectal cancer. Curr. Opin. Oncol. 13:307-313, 2001.

Cooper, H.S., Everley, L., Chang, W-C., Pfeiffer, G., Lee, B., Murthy, S., Clapper, M.L. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121:1407-1416, 2001.

Drummond, J.T., Bellacosa, A. Human DNA mismatch repair in vitro operates independently of methylation status at CpG sites. Nucl. Acids Res. 29:2234-2243, 2001.

Fava, T., Desnoyers, R., Schulz, S., Park, J., Weinberg, D., Mitchell, E., Waldman, S.A. Ectopic expression of GC-C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol. 19:3951-3959, 2001.

Fiumicino, S., Ercoli, A., Ferrandina, G., Hess, P., Raspaglio, G., Genuardi, M., Rovella, V., Bellacosa, A., Cicchillitti, L., Mancuso, S., Bignami, M., Scambia, G. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J. Clin. Oncol. 19:1008-1014, 2001.

Lucci-Cordisco, E., Carrara, S., Rovella, V., Del Tin, L., Percesepe, A., Pedroni, M., Caluseriu, O., Bellacosa, A., Anti, M., Neri, G., Ponz de Leon, M., Viel, A., Genuardi, M. Mutations of the minor mismatch repair gene MSH6 in typical and atypical hereditary non-polyposis colorectal cancer. Familial Cancer 1(2):93-9, 2001.

Mandelblatt, J.S., Berg, C.D., Meropol, N.J., Edge, S.B., Gold, K., Hwang, Y-T., Hadley, J. Measuring and predicting surgeons' practice styles for breast cancer treatment in older women. Medical Care 39:228-242, 2001.

Mandelblatt, J.S., Bierman, A.S., Gold, K., Zhang, Y., Ng, J.H., Maserejan, N., Hwang, Y-T., Meropol, N.J., Hadley, J., Silliman, R.A. Constructs of burden of illness in older breast cancer patients: a comparison of measurement methods. Health Services Res. Dec;36(6 Pt 1):1085-107, 2001.

Meropol, N.J., Niedzwiecki, D., Hollis, D., Schilsky, R.L., Mayer, R.J. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer. Cancer 91:1256-1263, 2001.

Myers, R.E., Turner, B., Weinberg, D., Hauck, W.W., Hyslop, T., Brigham, T., Rothermel, T., Grana, J., Schlackman, N. Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Prev. Med. 33:249-260, 2001.

Newschaffer, C.J., Topham, A., Weiner, S., Herzberg, T., Weinberg, D.S. The risk of colorectal cancer after breast cancer. Lancet 357:837-840, 2001.

Pingpank, J.F., Hoffman, J.P., Ross, E.A., Cooper, H.S., Meropol, N.J., Freedman, G., Pinover, W.H., LeVoyer, T.E., Sasson, A.R., Eisenberg, B.L. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J. Gastrointest. Surg. 5:121-130, 2001.

Rothenberg, M.L., Meropol, N.J., Poplin, E.A., Van Cutsem, E., Wadler, S. Mortality associated with irinotecan + bolus 5-fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19(18):3801-3807, 2001.

Sasson, A.R., Hoffman, J.P., Ross, E., Meropol, N.J., Szarka, C.E., Freedman, G., Pinover, W., Pingpank, J.F., Eisenberg, B.L. Trimodality therapy for advanced gallbladder cancer. Am. Surg. 67:277-284, 2001.

Sweed, M.R., Meropol, N.J. Assessment, diagnosis, and staging. In Contemporary issues in colorectal cancer: a nursing perspective, edited by D.T. Berg. Jones and Bartlett Publishers, Sudbury, Massachusetts, pp. 65-79, 2001.

Szarka, C.E., Yao, K-S., Pfeiffer, G.R., Balshem, A.M., Litwin, S., Frucht, H., Goosenberg, E.B., Engstrom, P.F., Clapper, M.L., O'Dwyer, P.J. Chronic dosing of oltipraz in people at increased risk for colorectal cancer. Cancer Detect. Prev. 25: 352-361, 2001.

von Mehren, M., Arlen, P., Gulley, J., Rogatko, A., Cooper, H.S., Meropol, N.J., Alpaugh, R.K., Davey, M., McLaughlin, S., Beard, M.T., Tsang, K.Y., Schlom, J., Weiner, L.M. The influence of GM-CSF and prior chemotherapy on the immunologic response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7:1181-1191, 2001.

Weinberg, D.S., Heyt, G., Cavanagh, M., Pitchon, D., McGlynn, K.A., London, W.T. A case-control study of CCK and gastrin levels in pancreatic adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 10:721-722, 2001.

Clapper ML, Chang W-C, Meropol, NJ. Chemoprevention of Colorectal Cancer. Curr Opinion Oncol 13: 307-313, 2001.

Sweed MR, Meropol NJ. Assessment, diagnosis, and staging. In: Contemporary issues in colorectal cancer: a nursing perspective. Berg DT, ed. Jones and Bartlett Publishers, Sudbury, Massachusetts, pp. 65-79, 2001.

Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P; Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys 51:19-27, 2001.

Medical Oncology

Director, Gastrointestinal Cancer Program;
Director, Gastrointestinal Tumor Risk Assessment Program

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

To make an appointment, call:
215-728-2570.

For general information, call:
1-888-FOX CHASE.
An oncology certified nurse will assist you.

Back to Dr. Meropol's Directory Page